BCMA Combinations in Multiple Myeloma
Too many loved ones live with uncertainty.
Let’s find answers.
Multiple myeloma is the second most common blood cancer in the US. It originates in the bone marrow and is characterized by abnormalities in plasma cells that reproduce uncontrollably in the bone marrow and other disease sites. Multiple myeloma is currently incurable for most patients as relapses occur despite the availability of several treatment options.
Let’s try a team approach
Several BCMA-targeted therapies have demonstrated promising clinical activity in patients with multiple myeloma. We believe that by inhibiting gamma secretase with nirogacestat, membrane-bound BCMA can be preserved, thereby increasing target density while simultaneously reducing levels of soluble BCMA, which may interfere with BCMA-directed therapies. In preclinical models of human multiple myeloma, nirogacestat has shown the ability to meaningfully enhance the activity of BCMA-targeted therapies. We are currently studying nirogacestat in multiple myeloma patients through clinical collaborations with industry-leading developers of BCMA therapies.
The safety and efficacy of nirogacestat in multiple myeloma has not been established.